252 related articles for article (PubMed ID: 33852862)
1. Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies.
Murin CD; Gilchuk P; Ilinykh PA; Huang K; Kuzmina N; Shen X; Bruhn JF; Bryan AL; Davidson E; Doranz BJ; Williamson LE; Copps J; Alkutkar T; Flyak AI; Bukreyev A; Crowe JE; Ward AB
Cell Rep; 2021 Apr; 35(2):108984. PubMed ID: 33852862
[TBL] [Abstract][Full Text] [Related]
2. Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk.
King LB; West BR; Moyer CL; Gilchuk P; Flyak A; Ilinykh PA; Bombardi R; Hui S; Huang K; Bukreyev A; Crowe JE; Saphire EO
Nat Commun; 2019 Apr; 10(1):1788. PubMed ID: 30996276
[TBL] [Abstract][Full Text] [Related]
3. Structural and molecular basis for Ebola virus neutralization by protective human antibodies.
Misasi J; Gilman MS; Kanekiyo M; Gui M; Cagigi A; Mulangu S; Corti D; Ledgerwood JE; Lanzavecchia A; Cunningham J; Muyembe-Tamfun JJ; Baxa U; Graham BS; Xiang Y; Sullivan NJ; McLellan JS
Science; 2016 Mar; 351(6279):1343-6. PubMed ID: 26917592
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein.
Gilchuk P; Kuzmina N; Ilinykh PA; Huang K; Gunn BM; Bryan A; Davidson E; Doranz BJ; Turner HL; Fusco ML; Bramble MS; Hoff NA; Binshtein E; Kose N; Flyak AI; Flinko R; Orlandi C; Carnahan R; Parrish EH; Sevy AM; Bombardi RG; Singh PK; Mukadi P; Muyembe-Tamfum JJ; Ohi MD; Saphire EO; Lewis GK; Alter G; Ward AB; Rimoin AW; Bukreyev A; Crowe JE
Immunity; 2018 Aug; 49(2):363-374.e10. PubMed ID: 30029854
[TBL] [Abstract][Full Text] [Related]
5. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine.
Kimble JB; Malherbe DC; Meyer M; Gunn BM; Karim MM; Ilinykh PA; Iampietro M; Mohamed KS; Negi S; Gilchuk P; Huang K; Wolf YI; Braun W; Crowe JE; Alter G; Bukreyev A
J Virol; 2019 Feb; 93(4):. PubMed ID: 30518655
[TBL] [Abstract][Full Text] [Related]
6. Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development.
Murin CD; Gilchuk P; Crowe JE; Ward AB
Front Immunol; 2021; 12():808047. PubMed ID: 35082794
[TBL] [Abstract][Full Text] [Related]
7. The Tetherin Antagonism of the Ebola Virus Glycoprotein Requires an Intact Receptor-Binding Domain and Can Be Blocked by GP1-Specific Antibodies.
Brinkmann C; Nehlmeier I; Walendy-Gnirß K; Nehls J; González Hernández M; Hoffmann M; Qiu X; Takada A; Schindler M; Pöhlmann S
J Virol; 2016 Dec; 90(24):11075-11086. PubMed ID: 27707924
[TBL] [Abstract][Full Text] [Related]
8. Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization.
Gilchuk P; Murin CD; Milligan JC; Cross RW; Mire CE; Ilinykh PA; Huang K; Kuzmina N; Altman PX; Hui S; Gunn BM; Bryan AL; Davidson E; Doranz BJ; Turner HL; Alkutkar T; Flinko R; Orlandi C; Carnahan R; Nargi R; Bombardi RG; Vodzak ME; Li S; Okoli A; Ibeawuchi M; Ohiaeri B; Lewis GK; Alter G; Bukreyev A; Saphire EO; Geisbert TW; Ward AB; Crowe JE
Immunity; 2020 Feb; 52(2):388-403.e12. PubMed ID: 32023489
[TBL] [Abstract][Full Text] [Related]
9. Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.
Wec AZ; Herbert AS; Murin CD; Nyakatura EK; Abelson DM; Fels JM; He S; James RM; de La Vega MA; Zhu W; Bakken RR; Goodwin E; Turner HL; Jangra RK; Zeitlin L; Qiu X; Lai JR; Walker LM; Ward AB; Dye JM; Chandran K; Bornholdt ZA
Cell; 2017 May; 169(5):878-890.e15. PubMed ID: 28525755
[TBL] [Abstract][Full Text] [Related]
10. Two Distinct Lysosomal Targeting Strategies Afford Trojan Horse Antibodies With Pan-Filovirus Activity.
Wirchnianski AS; Wec AZ; Nyakatura EK; Herbert AS; Slough MM; Kuehne AI; Mittler E; Jangra RK; Teruya J; Dye JM; Lai JR; Chandran K
Front Immunol; 2021; 12():729851. PubMed ID: 34721393
[TBL] [Abstract][Full Text] [Related]
11. Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma.
Gilchuk P; Guthals A; Bonissone SR; Shaw JB; Ilinykh PA; Huang K; Bombardi RG; Liang J; Grinyo A; Davidson E; Chen EC; Gunn BM; Alter G; Saphire EO; Doranz BJ; Bukreyev A; Zeitlin L; Castellana N; Crowe JE
Front Immunol; 2021; 12():706757. PubMed ID: 34335620
[TBL] [Abstract][Full Text] [Related]
12. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region.
Flyak AI; Kuzmina N; Murin CD; Bryan C; Davidson E; Gilchuk P; Gulka CP; Ilinykh PA; Shen X; Huang K; Ramanathan P; Turner H; Fusco ML; Lampley R; Kose N; King H; Sapparapu G; Doranz BJ; Ksiazek TG; Wright DW; Saphire EO; Ward AB; Bukreyev A; Crowe JE
Nat Microbiol; 2018 Jun; 3(6):670-677. PubMed ID: 29736037
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus.
Audet J; Wong G; Wang H; Lu G; Gao GF; Kobinger G; Qiu X
Sci Rep; 2014 Nov; 4():6881. PubMed ID: 25375093
[TBL] [Abstract][Full Text] [Related]
14. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection.
Williamson LE; Flyak AI; Kose N; Bombardi R; Branchizio A; Reddy S; Davidson E; Doranz BJ; Fusco ML; Saphire EO; Halfmann PJ; Kawaoka Y; Piper AE; Glass PJ; Crowe JE
J Virol; 2019 Apr; 93(8):. PubMed ID: 30728263
[TBL] [Abstract][Full Text] [Related]
15. Pan-ebolavirus protective therapy by two multifunctional human antibodies.
Gilchuk P; Murin CD; Cross RW; Ilinykh PA; Huang K; Kuzmina N; Borisevich V; Agans KN; Geisbert JB; Zost SJ; Nargi RS; Sutton RE; Suryadevara N; Bombardi RG; Carnahan RH; Bukreyev A; Geisbert TW; Ward AB; Crowe JE
Cell; 2021 Oct; 184(22):5593-5607.e18. PubMed ID: 34715022
[TBL] [Abstract][Full Text] [Related]
16. Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge.
Chen G; Koellhoffer JF; Zak SE; Frei JC; Liu N; Long H; Ye W; Nagar K; Pan G; Chandran K; Dye JM; Sidhu SS; Lai JR
ACS Chem Biol; 2014 Oct; 9(10):2263-73. PubMed ID: 25140871
[TBL] [Abstract][Full Text] [Related]
17. Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap.
Ilinykh PA; Santos RI; Gunn BM; Kuzmina NA; Shen X; Huang K; Gilchuk P; Flyak AI; Younan P; Alter G; Crowe JE; Bukreyev A
PLoS Pathog; 2018 Aug; 14(8):e1007204. PubMed ID: 30138408
[TBL] [Abstract][Full Text] [Related]
18. Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic Epitope.
West BR; Moyer CL; King LB; Fusco ML; Milligan JC; Hui S; Saphire EO
mBio; 2018 Sep; 9(5):. PubMed ID: 30206174
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive functional analysis of N-linked glycans on Ebola virus GP1.
Lennemann NJ; Rhein BA; Ndungo E; Chandran K; Qiu X; Maury W
mBio; 2014 Jan; 5(1):e00862-13. PubMed ID: 24473128
[TBL] [Abstract][Full Text] [Related]
20. Structural Insights into Reovirus σ1 Interactions with Two Neutralizing Antibodies.
Dietrich MH; Ogden KM; Katen SP; Reiss K; Sutherland DM; Carnahan RH; Goff M; Cooper T; Dermody TS; Stehle T
J Virol; 2017 Feb; 91(4):. PubMed ID: 27928010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
